• PCV21 Cost Consequences of Acute Myocardial Infarction in Diabetic Patients-The First Year

    May 1, 1998, 00:00

  • PCV18 The Impact of Acute Renal Failure on Cost in Elderly Patients with Congestive Heart Failure

    May 1, 1998, 00:00

  • MGB3 Postmarketing Outcomes Studies- Benefits And Risks

    May 1, 1998, 00:00

  • CC4 Cost-Benefit Analysis of Recombinant Erythropoietin in Premature Neonates

    May 1, 1998, 00:00

  • PHB5 The Responsiveness of Disease-Specific And Generic Health Measures to Changes in the Severity of Osteoarthritis

    May 1, 1998, 00:00

  • PMH14 Schizophrenia Management- Does Managed Care Influence Length of Stay in U.S. Hospitals?

    May 1, 1998, 00:00

  • MGA1 Improving Clinical Outcomes by Integrating A Normalized, Standardized, Comparative Database into the Process of Clinical Quality Improvement

    May 1, 1998, 00:00

  • PMH11 Utlization Review of SSRI Therapy at A Mental Health Managed Care Organization

    May 1, 1998, 00:00

  • PGD1 The Effects of Community-Based Pharmaceutical Care Services on Asthma-Related Quality of Life

    May 1, 1998, 00:00

  • PIC1 Markov Chain Estimation of Life Expectancy of HIV-Infected Patients- Comparison of Two Treatment Alternatives

    May 1, 1998, 00:00

  • MHC3 Factors Predicting Potentially Inappropriate Psychotropic Prescribing for the Elderly

    May 1, 1998, 00:00

  • CVA1 Economic Outcomes of Carotid Endrterectomy for Stroke

    May 1, 1998, 00:00

  • PHB3 Psychometric Evaluation of SF-12 in Osteoarthritis Clinical Trials

    May 1, 1998, 00:00

  • CVA2 Cost-Effectiveness and Economic Efficiency- The Case of Statin Therapy in Secondary Prevention of Cornary Heart Disease

    May 1, 1998, 00:00

  • CC3 Modeling Side Effect Costs from Literature-Based Data- Steroid-Induced Side Effects in Renal Transplantation

    May 1, 1998, 00:00

  • PGD3 Cost-Utility Relation of the Treatment of Diabetic Foot Lesion with Hyperbaric Oxygene Therapy Versus Standard Therapy

    May 1, 1998, 00:00

  • CM2 Clinical Intervention Assessment- Implementation of Default Values for Expediting the Calculation of Cost Savings And Cost Avoidances

    May 1, 1998, 00:00

  • MHA6 Evaluation of Antidepressant Utilization Patterns and Associated Depression Diagnoses among Patients in A National Managed Care Organization

    May 1, 1998, 00:00

  • PMD6 Chronic Care Costs of New Medicare HMO Enrollees- Implications for Disease Management

    May 1, 1998, 00:00

  • MHA3 Comparison of Sumatriptan (IMITREX) and Over-the-Counter (OTC) Medication Use According to Migraine Severity

    May 1, 1998, 00:00

  • PIC8 Clinical And Economic Benefits of An Infectious Disease Approval Program

    May 1, 1998, 00:00

  • PMH7 A General Model of the Effects of Alternative Sedative-Hypnotic Agents on the Costs of Motor Vehicle Accidents

    May 1, 1998, 00:00

  • MHA5 SSRI Antidepressant Use in Primary Care in the United Kingdom- A Multivariate Analysis

    May 1, 1998, 00:00

  • CM1 Estimating the Costs And Outcomes for Different Disease Management Strategies- A Case Study of Cyomegalovirus Infection And Disease

    May 1, 1998, 00:00

  • PGD11 Validity And Reliability of An American Translation of the St. Georges Respiratory Questionnaire

    May 1, 1998, 00:00

  • PMD13 Application of Pharmacoeconomics And Outcomes Research in Formulary Decision-Making

    May 1, 1998, 00:00

  • MM3 Development of Drug Use Performance Models as Measures of Patient Care

    May 1, 1998, 00:00

  • PMD12 The Paradox of League Tables

    May 1, 1998, 00:00

  • CM5 Discounting Health Benefits in Pharmacoeconomic Analyses- Is It Justified?

    May 1, 1998, 00:00

  • PHB7 The Direct Medical Cost of Osteporotic Fractures

    May 1, 1998, 00:00

  • CC5 Incremental Cost-Effectiveness Analysis Comparing 4-Layer Bandage System with And without Apligraf for the Outpatient Treatment of Venous Leg Ulcers

    May 1, 1998, 00:00

  • ID3 Prescribing Patterns for Treatment of Upper Respiratory Infections

    May 1, 1998, 00:00

  • PCV20 Convenience Implications of A Single Bolus Thrombolytic

    May 1, 1998, 00:00

  • PMH2 Assessment of Health-Related Quality of Life During Treatment of Opiate Dependence Using the Short Form-36

    May 1, 1998, 00:00

  • PMH3 Evaluation of Humanistic Outcomes for Patients on Selective Serotonin Reuptake Inhibitors

    May 1, 1998, 00:00

  • PMH12 Texas Medication Algorithm Project- Feasibility Study of Implementing Medication Algorithms in the Public Mental Health Sector

    May 1, 1998, 00:00

  • DA4 Construction of A Validated, Normalized, Granular Administrative Database And Its Use in Clinical Outcomes Improvement, Clinical Research, And Pharmacoeconomic Research

    May 1, 1998, 00:00

  • PIC6 Using A Pneumonia-Specific Severity of Illness Model in Assessing Variation in Hospital Length of Stay for Community-Acquired Pneumonia Patients

    May 1, 1998, 00:00

  • CVA6 Confounding by Indication in Calcium Channel Blocker Treatment of Hypertension or Angina

    May 1, 1998, 00:00

  • PMD10 The Development of A Patient Outcomes Software for Urologists- Capsure POS

    May 1, 1998, 00:00

  • PGD8 Comparison of Prevalence Rates of Low Back Disorders Obtained from Two Large National Claims Databases

    May 1, 1998, 00:00

  • PGD15 Veterans Satisfaction with H2-Receptor Antagonist (H2RA) Drug Conversion

    May 1, 1998, 00:00

  • PCV19 Evaluation of the Costs of Heart Failure in Belgium

    May 1, 1998, 00:00

  • PCV9 Study of Hypertensive Prescribing Practices

    May 1, 1998, 00:00

  • MHA4 SSRI Antidepressant Use Patterns and their Relation to Clinical Global Impressions Scores- A Naturalistic Study

    May 1, 1998, 00:00

  • PIC9 The Economic Impact of A Drug Information Service

    May 1, 1998, 00:00

  • PMH9 Month-to-Month Adherence with Antipsychotic Pharmacotherapy- A Comparison Between Atypical And Typical Antipsychotics

    May 1, 1998, 00:00

  • MM4 Reconciling Decision Models with the Real World- The Cost-Effectiveness of Erythropoietin for Esrd-Related Anemia

    May 1, 1998, 00:00

  • PIC7 Epoetin Alfa Administered to Academic Health Center Dialysis Patients- Comparison to HCFA Billing Records

    May 1, 1998, 00:00

  • UT3 The EuroQoL EQ-5D- An Outcome Measure for Use in Clinical And Economic Evaluation

    May 1, 1998, 00:00

  • DA8 Evaluating Health Outcomes And Pharmacoeconomic Literature

    May 1, 1998, 00:00

  • ID1 Randomised Prospective Study Comparing Cost-Effectiveness of Teicoplanin and Vancomycin As Second-Line Empiric Therapy for Infection in Neutropenic Patients

    May 1, 1998, 00:00

  • DA2 The Role of Patient Registries in Disease Management and Outcomes Research

    May 1, 1998, 00:00

  • PGD6 A Managed Care Cost Analysis of the Treatment of Psoriasis

    May 1, 1998, 00:00

  • CC6 Development of Asthma-Specific Outcomes Measures for Children

    May 1, 1998, 00:00

  • PMD9 Evaluation of A Pathway for Providing Pharmaceutical Care

    May 1, 1998, 00:00

  • PMD1 Information Technology in A Large Multi-Site Outcomes Study

    May 1, 1998, 00:00

  • MHB3 Cost-Effectiveness Evaluation of New Antipsychotics

    May 1, 1998, 00:00

  • PMH5 The Cost of Treating Schizophrenia in the California Medicaid (MEDI-CAL) Program

    May 1, 1998, 00:00

  • PCV15 Study of Procedure Costs And Outcomes Associated with the Pharmacological Treatment of Arterial Disease And Intermittant Claudication in the Department of Claudication in the Department of Defense

    May 1, 1998, 00:00

  • PIC4 Cost-Effectiveness of Piperacillin-Tazobactam Versus Ceftazidime in Patients with Febrile Neutropenia

    May 1, 1998, 00:00

  • PMD8 Prenatal Care And Birth Weight in the United States

    May 1, 1998, 00:00

  • MGA2 Disease Management in Hypertension- The Benefits of Meeting Guideline Goals for Blood Pressure

    May 1, 1998, 00:00

  • CVA3 Adherence to Hypertension Therapy- The Effect of Initial Drug Choice

    May 1, 1998, 00:00

  • PHB1 Efficient Strategies for Osteoporosis Testing

    May 1, 1998, 00:00

  • ID6 Cost-Effectiveness of Liposomal Daunorubicin Versus Liposomal Doxorubicin in Kaposi Sarcoma

    May 1, 1998, 00:00

  • CVB2 Development And Cross-Validation of A Comorbidity Index for A Stroke Population

    May 1, 1998, 00:00

  • ID5 Socio-Economic Relevance of Inpatient Treatment of Skin And Soft Tissue Infections with Tazobactam/Piperacillin 0.5 g/2.0 g in Comparison with Amoxicillin/Clavlanic Acid, Ceftriaxone, And Cefotaxime

    May 1, 1998, 00:00

  • PGD5 Predicting Hospitalization of Patients with Diabetes Mellitus- An Application of the Bayesian Discriminant Analysis

    May 1, 1998, 00:00

  • DM1 Interpreting And Using Costeffectiveness Results

    May 1, 1998, 00:00

  • DA6 Strategies for Formulary Comparisons in the Medicaid Managed Care Era

    May 1, 1998, 00:00

  • PGD7 Consequences of High Hematocrit Maintenance among Hemodialysis Patients

    May 1, 1998, 00:00

  • MM6 Decision Analysis- What is Its Utility for Pharmacoeconomic Analysis?

    May 1, 1998, 00:00

  • PMH1 The Economic Burden of Schizophrenia- Acute General Hospital Costs

    May 1, 1998, 00:00

  • PIC10 The Influence of Case Mix Bias On Costs of Hospitalisation for Lower Respiratory Tract Infection

    May 1, 1998, 00:00

  • MGB5 Adherence of Health Care Workers to Hepatitis B Vaccination (HBV) Policy is Influenced by Leadership

    May 1, 1998, 00:00

  • MHC5 The EuroQol in Parkinsons Disease Research- Rated Current Health vs. Population-Derived Health State Preferences

    May 1, 1998, 00:00

  • PCV8 Readiness to Comply And Outcomes of Antihypertensive Therapy

    May 1, 1998, 00:00

  • CM6 The Use of Patient Self-Reports to Collect Health Care Resource Utilization Data

    May 1, 1998, 00:00

  • PIC11 A Health Economic Evaluation of Paclitaxel And Carboplatin Versus Vinorelbine And Cisplatin Combination Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

    May 1, 1998, 00:00

  • PCV12 One-Year Clinical And Economic Outcomes of Primary Coronary Angioplasty Using A National Database

    May 1, 1998, 00:00

  • PCV13 Prevalence And Cost of Hospitalizations Due to Angina in the United States Using A National Database

    May 1, 1998, 00:00

  • PCV3 How Does Gender Affect Pharmacotherapy Treatment Decisions for Hypercholesterolemia/Hyperlipidemia?

    May 1, 1998, 00:00

  • PCV11 The Impact of Unstable Angina on the Use of Medical Resources in Italy

    May 1, 1998, 00:00

  • UT1 Trade-Off Preferences for Pharmaceutical Development, Marketing, And Outcomes Evaluation

    May 1, 1998, 00:00

  • PMH16 A Health Policy Analysis of Pharmacotherapy for Major Depressive Disorder in Europe And the Americas

    May 1, 1998, 00:00

  • UT2 Practical Applications of the Health Utilities Index

    May 1, 1998, 00:00

  • CVB6 Torsemide And Furosemide in the Treatment of the EDEMA of Heart Failure- Interim Results of A Randomized Effectiveness Trial

    May 1, 1998, 00:00

  • PMH13 Developing A Task-Based Instrument to Measure Migraine-Related Productivity

    May 1, 1998, 00:00

  • MGB4 Relationship Between Quality of Life, Disease Severity, And Physician Visits in Managed Care Patients with Atopic Dermatitis

    May 1, 1998, 00:00

  • MM1 Monte Carlo Simulation in Health Care Models

    May 1, 1998, 00:00

  • PHB8 Cost-Effectiveness of Hormone Therapy Versus Calcium Therapy- An Osteoporosis Markov Model

    May 1, 1998, 00:00

  • GIR2 Noncompliance with Dosing Instructions And Gastrointestinal Outcomes Associated with Alendronate for Osteoporosis in A Large HMO

    May 1, 1998, 00:00

  • Editorial

    May 1, 1998, 00:00

  • GIR6 Predictors of Diagnostic-Related Group Day Outliers in the Medicare End-Stage Renal Disease Population

    May 1, 1998, 00:00

  • PHB6 Health Care Use in Women Age 45 And Older

    May 1, 1998, 00:00

  • PGD10 Bambuterol is A More Cost-Effective Treatment than Salmeterol in Asthma Patients with Nocturnal Symptoms

    May 1, 1998, 00:00

  • PMD3 Use of Administrative Data to Create Disease-Specific Datasets for Use in Health Economic Studies

    May 1, 1998, 00:00

  • CVB3 Evaluation of the Costs of Coronary Heart Disease in Belgium

    May 1, 1998, 00:00

  • CVB5 Preventing Cardiovascular Disease- Is Primary Prevention with Pravastatin Worth the Money?

    May 1, 1998, 00:00

  • PGD9 Outcomes And Cost-Benefit of Inhaled Corticosteroid Therapy Introduction in Medicaid-Enrolled Asthmatic Children

    May 1, 1998, 00:00

  • MM7 Issues in Developing Economic Models for Managed Care- The Case of Osteoporosis Prevention

    May 1, 1998, 00:00

  • DA5 Disease State Management Tracker- Implementing, Tracking, And Evaluating Clinical Pathways And Outcomes

    May 1, 1998, 00:00

  • PMH15 Development of A Self-Administered Outcome Measure for Use in An Outpatient Population of Individuals with Schizophrenia

    May 1, 1998, 00:00

  • PHB9 Use of Centralized Pharmacy Records in A Managed Care Organization to Determine Effect of Educational Material on Hormone Replacement Therapy Patient Compliance

    May 1, 1998, 00:00

  • GIR4 Prospective Economic Evaluation in A Phase IIIB Renal Transplant Clinical Trial

    May 1, 1998, 00:00

  • PCV6 Development of A Decision-Analytic Model of Stroke Care in us And Europe

    May 1, 1998, 00:00

  • PCV2 An Analysis of the Economics of Hypertension

    May 1, 1998, 00:00

  • CC1 Socioeconomic Efficiency of Prophylaxis of Exacerbations with N-Acetylcysteine in Patients with Chronic Bronchitis

    May 1, 1998, 00:00

  • PMD17 Surveillance of A New Drug in the United Kingdom

    May 1, 1998, 00:00

  • MHB1 Treatment Choice And the Incidence And Economic Intensity of Hospital Inpatient Use by Depressed Patients

    May 1, 1998, 00:00

  • MGB6 Formulary Impact Decision Modeling in HMG-COA Reductase Inhibitors

    May 1, 1998, 00:00

  • PGD2 The Economic Implications of Decreased Patient Adherence to Co-Prescribed Diclofenac And Misoprostol (CORX-DM) Relative to A Single-Tablet Formulation of Diclofenac/Misoprostol (STF-D/M)

    May 1, 1998, 00:00

  • MHC4 Testing The Reliability of Generic Quality-of-Life Measures in the Study of Multiple Sclerosis

    May 1, 1998, 00:00

  • PCV10 Medical And Economic Outcomes in Patients Treated with Diltiazem or Digoxin for Atrial Fibrillation- A Database Analysis

    May 1, 1998, 00:00

  • PGD4 Cost-Effectiveness Analysis of Screening of Type II Diabetes Mellitus in Nonpregnant Adults

    May 1, 1998, 00:00

  • PCV4 Empirical Analysis of the Cost-Efficiency of HMG-COA Reductase Inhibitors

    May 1, 1998, 00:00

  • GIR1 Economic And Clinical Outcomes Models for the Evaluation of Drug Therapy Strategies in Treatment of Gerd

    May 1, 1998, 00:00

  • CVA5 Effect of Compliance on Health And Economic Outcomes- Role of Conjugated Estrogen on Depression And Cardiovascular Disorders

    May 1, 1998, 00:00

  • PMH8 Duration of Continuous Therapy Between Atypical And Typical Antipsychotics

    May 1, 1998, 00:00

  • PMD14 Vox Populi- Stated Preferences for Pharmaceutical Innovations

    May 1, 1998, 00:00

  • DM2 Dissemination of Pharmacoeconomic Results to Managed Care Organizations

    May 1, 1998, 00:00

  • PCV14 Nonparametric Analysis of Cost-Effectiveness Ratios of Pravastatin in Primary Prevention of Cardiovascular Disease

    May 1, 1998, 00:00

  • MM5 Comparing Computerized Options in Pharmacoeconomics- Spreadsheets, Decision Trees, And Educational Tools- An Open Workshop for Demonstrating Software

    May 1, 1998, 00:00

  • GIR3 Cost-Effectiveness of Proton Pump Inhibitors in Gastric ULCER

    May 1, 1998, 00:00

  • MGA6 Survey Strategies in the Revision of the Guidelines for Economic Evaluation- Canada

    May 1, 1998, 00:00

  • PMD7 The Value of Medicines- Is There Enough Economic Evidence?

    May 1, 1998, 00:00

  • PMH4 Quality of Life And Adverse Reactions in Depressed Patients Receiving Antidepressant Drugs

    May 1, 1998, 00:00

  • PCV16 Smoking Related Costs in the United States

    May 1, 1998, 00:00

  • PMH17 Utilization Patterns of Antidepressant Medications in A Patient Population Served by A Primary Care Medical Group

    May 1, 1998, 00:00

  • PCV1 Factors Influencing the Decision to Treat Serum Lipid Disorders by Drug Therapy in the Primary Care Venue

    May 1, 1998, 00:00

  • MHA1 The Economic Burden of Alzheimers Disease to Medicaid in California (MEDI-CAL)

    May 1, 1998, 00:00

  • PHB4 The Responsiveness of Disease-Specific And Generic Health Measures to Changes in the Severity of Rheumatoid Arthritis And to Treatment

    May 1, 1998, 00:00

  • MGA4 A Retrospective Approach to Evaluate Qaly- Estimation of Health Utility Index from the SF-36 in A Managed Care Population

    May 1, 1998, 00:00

  • PHB10 Quality of Life And Pharmacoeconomic Aspects of Hormone Replacement Therapy in Post-Menopausal Women-A Canadian Randomized Trial

    May 1, 1998, 00:00

  • PMD16 Implication of Preventing Disease on Life Years Gained (LYG)

    May 1, 1998, 00:00

  • PHB2 SF-12 Osteoarthritis-Specific Health Index- Development And Validation

    May 1, 1998, 00:00

  • MHC1 A Model of Primary Care Treatment of Major Depressive Disorder

    May 1, 1998, 00:00

  • PMH10 Selective Serotonin Reuptake Inhibitor Utilization Patterns- Consistency Across Research Designs

    May 1, 1998, 00:00

  • CVB1 Cost of Italian Hypertensive Patient- A Feasibility Study from the Pandora Project

    May 1, 1998, 00:00

  • DM3 Outcomes Research in Medication Use- HCFAS Health Care Quality Improvement Program

    May 1, 1998, 00:00

  • MHB6 Medical And Economic Relevance of Screening of Stroke Risk by Employees

    May 1, 1998, 00:00

  • PIC3 Colorectal Cancer Screening- Cost-Effectiveness Analysis from An Italian Viewpoint

    May 1, 1998, 00:00

  • DA1 Using Medication History to Measure Indication Bias

    May 1, 1998, 00:00

  • PIC5 Cost-Effectiveness Analysis of Piperacillin-Tazobactam Versus Imipenem-Cilastatin in the Treatment of Intra-Abdominal Infections

    May 1, 1998, 00:00

  • ID2 Willingness to Pay for HIV Prevention- A Study of High-And Low-Risk Groups

    May 1, 1998, 00:00

  • MHA2 Cost Impact of Using Olanzapine at A Veterans Affairs Medical Center

    May 1, 1998, 00:00

  • MHB4 Comparison of Standard Gamble, Time Trade-Off, And Visual Analog Scale Scores for Hypothetical Stroke Health States Using A Computer-Based Program

    May 1, 1998, 00:00

  • MGA3 A New Paradigm for Assessing Health-Related Quality of Life- A Social-Clinical Model

    May 1, 1998, 00:00

  • DA7 Prospective, Naturalistic Outcomes Measurement- The Schizophrenia Care And Assessment Program (SCAP)

    May 1, 1998, 00:00

  • DA3 Using Community Pharmacies to Conduct Outcomes Research

    May 1, 1998, 00:00

  • PCV17 Lipid Therapy And Cardiovascular Disease- How Many Americans Should be Treated?

    May 1, 1998, 00:00

  • PMD2 The Effect of the Louisiana Medicaid Lock-in on Prescription Drug Utilization And Expenditures

    May 1, 1998, 00:00

  • PHB11 Determining Minimally Important Changes (MIC) in Rheumatoid Arthritis (RA) Functional Status

    May 1, 1998, 00:00

  • PCV7 Economic Evaluation of Torasimide in Congestive Heart Failure in Germany

    May 1, 1998, 00:00

  • PGD13 Does the Duration of Pulmonary Rehabilitation Affect the Magnitude of Patient Response?

    May 1, 1998, 00:00

  • PGD14 A Health Economic Analysis of Fluticasone Propionate, Budesonide, And Beclomethasone Dipropionate for the Treatment of Moderate to Severe Asthma

    May 1, 1998, 00:00

  • MGB1 Poor Adherence to Hypertension Treatment Guidelines- An Analysis of Therapeutic Choices

    May 1, 1998, 00:00

  • MM2 Designing Computer Models to Convey Cost-Effectiveness Analyses Results

    May 1, 1998, 00:00

  • PMD5 Prescription Medication Use in Older Americans

    May 1, 1998, 00:00

  • CVB4 In-Hospital Survival of Congestive Heart Failure Patients Treated with Dobutamine or Milrinone

    May 1, 1998, 00:00

  • MGB2 The Utilization And Costs of Prescription Drugs in A Texas Medicaid Managed Care Pilot Program

    May 1, 1998, 00:00

  • PIC2 Socioeconomic Relevance of Inpatient Treatment of Intra-Abdominal Infections with Tazobactam/Piperacillin 0.5 g/4.0 g in Comparison with Imipenem/Cilastatin

    May 1, 1998, 00:00

  • CC2 Cost of Preventable Adverse Drug Events in Emergency Department Patients

    May 1, 1998, 00:00

  • PMD4 Outcomes Research Interests of A Community Pharmacist Research Network

    May 1, 1998, 00:00

  • MHB2 Medical Costs of Venlafaxine Versus Tricyclic or Tetracyclic Antidepressant Therapy After Switching from Selective Serotonin Reuptake Inhibitors

    May 1, 1998, 00:00

  • PCV5 Pharmaceutical Costs of Patient Non-Adherence to Lipid-Lowering Drug Therapy

    May 1, 1998, 00:00

  • PMD15 An Unbiased Method of Pharmaceutical Cost Analysis

    May 1, 1998, 00:00

  • MGA5 Health Utilities Index- Further Evidence of Responsiveness

    May 1, 1998, 00:00

  • MHC2 Medical And Economic Outcomes of Noncompliance with Dilantin in Adult Medicaid Epileptics

    May 1, 1998, 00:00

  • PGD12 Cost of Prescription Drugs And Cost of Treatment Failure for Sinusitis

    May 1, 1998, 00:00

  • PMD11 Use of Administrative Databases in Saskatchewan, Canada, for Pharmacoeconomic and Outcomes Research

    May 1, 1998, 00:00

  • PMH6 Economic Outcomes of Antidepressant Use in A Managed Care Organization

    May 1, 1998, 00:00

  • CM4 Use of UB-92S And Medicare Cost Reports in A Large, Multi-Center Randomized Trial- The Pursuit Experience

    May 1, 1998, 00:00

  • CM3 Multivariable Methods for Measuring Treatment Costs in Randomized Trials

    May 1, 1998, 00:00

  • MHB5 Changes in Sexual Function And Bother in Men Treated for Prostate Cancer- Results from the Capsure Database

    May 1, 1998, 00:00
  • «
  • 181
  • 182 (current)